Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
POZN > SEC Filings for POZN > Form 8-K on 20-Aug-2014All Recent SEC Filings

Show all filings for POZEN INC /NC

Form 8-K for POZEN INC /NC


20-Aug-2014

Entry into a Material Definitive Agreement


Item 1.01. Entry Into A Material Definitive Agreement.

On May13, 2014, POZEN Inc., a Delaware corporation ("POZEN"), Glaxo Group Limited, d/b/a GlaxoSmithKline ("GSK"), CPPIB Credit Investments Inc. ("CII") and Pernix Therapeutics Holdings, Inc. ("Pernix"), entered into certain agreements in connection with GSK's divestiture of all of its rights, title and interest to develop, commercialize and sell Treximet® (sumatriptan/naproxen sodium) in the U.S. (the "Divestiture") to Pernix which are described in a Form 8-K filed by POZEN on May 14, 2014.

As described in the Form 8-K filed on May 14, 2014, upon the closing of the Divestiture, which occurred on August 20, 2014, GSK assigned the Product Development and Commercialization Agreement executed as of June 11, 2003 between POZEN and GSK (the "Agreement") to Pernix. Immediately following the closing of the Divestiture, Amendment No. 1 to the Agreement ("Amendment No. 1") between POZEN and Pernix became effective.

On July 30, POZEN, Pernix, and Worrigan Limited, an affiliate of Pernix formed under the laws of Ireland ("Worrigan"), entered into a Second Amendment to the Agreement ("Amendment No. 2") which permits Worrigan, the assignee of Pernix's rights under the Agreement, to further assign the Agreement without POZEN's prior written consent as collateral security for the benefit of purchasers of debt securities issued by Pernix to finance the Divestiture. Amendment No. 2 became effective upon the closing of the Divestiture.

The foregoing is a summary of the material terms of Amendment No. 2 and does not purport to be complete and is qualified in its entirety by reference to the full text of such agreements which will be filed as exhibits to the Company's next Quarterly Report on Form 10-Q.


  Add POZN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for POZN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.